Lumida
/ALNY
⌘K
Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

ALNY
$248.68USD+0.47%+1.17 today

MARKET CAP

33.3B

P/E (TTM)

43.8x

FWD P/E

29.9x

DAY RANGE

$246 – $254

52W RANGE

$198
$496

AI Summary

Stalk
Buy NowMedium

ALNY has failed to sustain downside control and has entered a structural repair phase marked by a Bullish Pivot Point and ongoing Lockout Rally dynamics. Price is tightly tracking the rising 9- and 20-day EMAs, offering a favorable buy-on-dip zone. Medium-term continuation patterns (higher highs and lows) support bullish participation, while the long-term downtrend under the 200-day SMA remains an overarching risk.

  • Q1 2026 revenue $1.0B, up 121% YoY with $910M from TTR
  • Amvuttra holds ~80% of new TTR prescriptions and 90% patient adherence
  • Valuation implies high expectations, risking downside if growth slows
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$844.3M$1.0B$1.8B$2.2B$3.7B
YoY %+71.3%+22.9%+76.2%+23.0%+65.2%
P / Sales23.8x27.4x13.3x13.4x14.4x
EV / Sales26.4x30.1x15.1x14.8x15.1x
Gross Profit, Adj.$729.3M$897.2M$1.6B$1.9B$3.0B
YoY %+75.8%+23.0%+73.9%+24.5%+56.4%
Margin %86.4%86.5%85.3%86.4%81.8%
EV / Gross Profit30.6x34.8x17.7x17.1x18.5x
EBITDA, Adj.$-661.1M$-740.6M$-228.1M$-120.2M$557.2M
YoY %+16.7%-12.0%+69.2%+47.3%+563.5%
Margin %-78.3%-71.4%-12.5%-5.3%15.0%
EV / EBITDA-33.8x-42.2x-120.9x-276.5x100.6x
EBIT$-708.7M$-785.1M$-282.2M$-176.9M$501.6M
YoY %+14.5%-10.8%+64.1%+37.3%+383.6%
Margin %-83.9%-75.7%-15.4%-7.9%13.5%
EV / EBIT-31.5x-39.8x-97.8x-187.9x111.8x
Net Income$-852.8M$-1.1B$-440.2M$-278.2M$313.7M
YoY %+0.6%-32.6%+61.1%+36.8%+212.8%
Net Margin-101.0%-109.0%-24.1%-12.4%8.4%
EPS (GAAP)-$7.20-$9.30-$3.52-$2.18$2.33
YoY %+3.5%-29.2%+62.2%+38.1%+206.9%